Boehringer Ingelheim Press Releases

Boehringer Ingelheim and Vectura conclude collaboration

Boehringer Ingelheim and GlaxoSmithKline back EFA`s call for urgent improvements in care for people with lung disease this World COPD Day

Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder (HSDD)

Boehringer Ingelheim announces record productivities for CHO cells using the BI-HEX technology platform

Heinrich Wieland Prize 2009 awarded for outstanding achievements in the synthesis of key natural products

Boehringer Ingelheim Animal Health closes deal to acquire a significant portion of the Fort Dodge Animal Health Business from Pfizer

CHMP issues positive opinion for Micardis® (telmisartan) as the first treatment in its class to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients

FDA approves Twynsta® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

FDA approves Micardis® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors

Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease

Access to HIV medication

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin

Boehringer Ingelheim Animal Health enters into agreement to acquire certain assets of Fort Dodge Animal Health from Pfizer

New analysis supports tiotropium as initial maintenance therapy for COPD

Early administration of Aggrenox® is effective and safe after acute ischaemic stroke or TIA

ERS COPD Research Award 2009 sponsored by Boehringer Ingelheim

New data show patients with chronic low back pain maintained pain reduction on duloxetine

Groundbreaking results in the RE-LY® trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding!